Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis

Jordi Gratacós, Caridad Pontes*, Xavier Juanola, Jesús Sanz, Ferran Torres, Cristina Avendaño, Antoni Vallano, Gonzalo Calvo, Eugenio De Miguel, Raimon Sanmartí, Miriam Almirall, Maria Aparicio, Agustí Sellas, Roser Vives, Nestor Albiñana, Mireia Moreno, Teresa Clavaguera, Juan Carlos Torre-Alonso, Raúl Veroz, Carlos Rodríguez-LozanoLuís Francisco Linares, Ana Urruticoechea, Eduardo Collantes, Rosa María Morlà, Dèlia Reina, Eduardo Cuende, Pedro Zarco, Maria Cruz Fernández-Espartero, Rosario García-Vicuña, Carlos Alberto Montilla, Alejandro Villalba, Dora Pascual, Cristina Campos, Antonio Juan, Rafael Ariza, Consuelo Díaz-Miguel, Manuel Maqueda, Maria Pilar Fernández-Dapica, Manuel Fernández-Prada, Enrique Batlle, Carlos González-Fernández, Rubén Queiro

*Autor corresponent d’aquest treball

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

40 Cites (Scopus)

Resum

Objective: The objective was to determine if dose reduction is non-inferior to full-dose TNFi to maintain low disease activity (LDA) in patients already in remission with TNFi, in axial spondyloarthritis. Methods: Randomized, parallel, non-inferiority, open-label multicentre clinical trial. Patients were eligible if they had axial spondyloarthritis and had been in clinical remission for ≥ 6 months with any available TNFi (adalimumab, etanercept, infliximab, golimumab) at the dose recommended by product labelling. Patients were randomized by automated central allocation to continue the same TNFi dose schedule, or to reduce the dose by roughly half according to the protocol. The main outcome was the proportion of subjects with LDA after 1 year. Serious adverse reactions or infections were recorded. Results: The trial stopped due to end of the funding period, after 126 patients were randomized; 113 patients (84.1% male, mean age (SD) 45.6 (13.0) years) were included in the main per-protocol subset. Non-inferiority was concluded for LDA at 1 year (47/55 (83.8%) patients in the full-dose and 48/58 (81.3%) patients in the reduced-dose arm, adjusted difference (95% CI) - 2.5% (- 16.6% to 11.7%)). Serious adverse reactions or infections were reported in 7/62 patients (11.3%) assigned to full dose and 2/61 patients (3.3%) assigned to reduced dose (p value = 0.164). Conclusion: In patients with ankylosing spondylitis in clinical remission for at least 6 months, dose reduction is non-inferior to full TNF inhibitor doses to maintain LDA after 1 year. Serious adverse events may be less frequent with reduced doses. Trial registration: EU Clinical Trials Registry, EudraCT 2011-005871-18 and ClinicalTrials.gov, NCT01604629.

Idioma originalAnglès
Número d’article11
Pàgines (de-a)11
Nombre de pàgines10
RevistaArthritis Research and Therapy
Volum21
Número1
DOIs
Estat de la publicacióPublicada - 8 de gen. 2019

Fingerprint

Navegar pels temes de recerca de 'Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis'. Junts formen un fingerprint únic.

Com citar-ho